Drug intelligence / Profile preview

Bio 25

Development stage: Phase 4
Lead developer: Ambrosia-SupHerb
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Bio 25 is a high-potency, multi-strain probiotic dietary supplement manufactured by the Israeli company Supherb. It contains 11 distinct strains of beneficial bacteria, including species from the *Lactobacillus* and *Bifidobacterium* genera, with a concentration of 25 billion active organisms per capsule. The formulation is designed to restore and maintain a healthy balance of gut microbiota. In clinical research, specifically a Phase 4 trial at The Baruch Padeh Medical Center, Poriya, Bio 25 has been evaluated for its ability to improve recovery rates and reduce inflammatory markers in patients with Crohn's disease exacerbations. The supplement is intended to modulate the intestinal immune response and support mucosal barrier integrity.

Brand names: Bio 25Bio25Bio-25
Other names: Supherb Bio 25

Beyond the preview

Go deeper on Bio 25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio 25.

Explore the full profile